Foundation Medicine retweeted
New #JITC article: Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types bit.ly/40P4spH @RyonGraf @FoundationATCG
Foundation Medicine retweeted
Biotechnology firm Foundation Medicine is consolidating its 1,100 Massachusetts employees into a 630,000-square-foot-building in the Seaport, the latest company to set up shop in the bustling business district. trib.al/ZGcDzOG
Foundation Medicine retweeted
Mark your calendars! Join us on January 18th at 12:30 p.m. as we dive into an insightful discussion on lung cancer disparities and research opportunities with Dr. @JhanelleGray and @LUNGevity. Let's work towards a more inclusive future for all!
We’re just 8 days away from our LinkedIn Live event with @MoffittNews & @LUNGevity, where we’ll dive into topics around disparities in #lungcancer, current research and opportunities for a more inclusive future. Learn more and join us here: bit.ly/FMILiveJan2024
Foundation Medicine retweeted
Sponsor Content: @FoundationATCG’s @DrMiaLevy discusses how circulating tumor DNA testing can be incorporated into oncology decisionmaking, at a #PeopleVCancer Underwriter Session produced by Foundation Medicine.
Join the summit: youtube.com/watch?v=CZNP_Z62…
Foundation Medicine retweeted
Distinct Cancer Drivers, Markers Detected in Tumor Samples from African Ancestry Patients. With hundreds of thousands of tumor samples, researchers unearthed genetic alterations that are enriched or diminished among African ancestry individuals. ow.ly/9gFX104Z91I
Foundation Medicine retweeted
BLOODPAC is thrilled to welcome Elizabeth Mansfield to our Scientific Co-Chair Committee! Liz has over 20 years of experience in regulatory affairs, including a decade of service at the FDA, and is a longtime member of our Analytical Validation working groups. @FoundationATCG
Foundation Medicine retweeted
👀 Check out what’s popular this week in #JCOPO:
"Tumor Mutational Burden in Real-World Patients With #PancreaticCancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness" ➡️ fal.cn/3zTVz @FoundationATCG @Amitmahipal79 #pancsm
Foundation Medicine retweeted
Integrative Analysis of a Large Real-world Cohort of #SmallCellLungCancer Identifies Distinct Genetic Subtypes and Insights into Histological Transformation— by @smruthy90, @SageJulien, @christine_lovly et al.
https://nitter.gq/t.co/59eYVFFOzF
@FoundationATCG @Stanford @VUMC_Cancer
Foundation Medicine retweeted
Foundation Medicine, Natera Launch Early Access for Clinical Personalized ctDNA Monitoring Test. The personalized and targeted tumor assay, also available for research use in clinical trials, provides a surrogate measure of tumor burden from blood samples. ow.ly/mVXq104sfw1
Foundation Medicine retweeted
.@FoundationATCG & @NateraGenetics provide early access to personalized circulating tumor DNA monitoring assay.
cancerletter.com/drugs-and-t…
Foundation Medicine retweeted
SPONSORED CONTENT: In a Underwriter Session produced by Foundation Medicine, @FoundationATCG‘s @xelamb speaks with @YaleCancer @SmilowCancer’s @PamelaKunzMD at #PeopleVCancer about the collective responsibility to ensure equity in access to care, clinical trials, new therapies
Foundation Medicine retweeted
We’re LIVE at #PeopleVCancer, underwritten by @bmsnews, @FoundationATCG, @PhRMA, & @TakedaPharma. Join us as we explore the latest scientific breakthroughs reshaping patient care and treatment, and renewing optimism within the cancer community.
Tune in: youtube.com/watch?v=i_wHzNR0…
Foundation Medicine retweeted
For young adults cancer patients in remission, fear of recurrence and even PTSD can become the new normal. More: on.theatln.tc/atlYwSX
We'll gather the cancer community on 11/3 at #PeopleVCancer, underwritten by @FoundationATCG, @PhRMA, & @TakedaPharma: on.theatln.tc/tBjalNJ
Foundation Medicine retweeted
Ariel Bourla sat down w/ @JournPrecMed to discuss a study done in partnership w/@FoundationATCG & @Genentech, that found potential for an add'l diagnostic approach to personalized NSCLC therapy. More on the thought & design behind this innovative study. https://nitter.gq/t.co/rXtYMSyixr
Foundation Medicine retweeted
ICYMI in @CD_AACR: The #Genomics of #ColorectalCancer in Populations with African & European Ancestry @MontefioreNYC @ae_cancercenter @EinsteinMed @FoundationATCG #AACRdisp22 aacrjournals.org/cancerdisco…
Foundation Medicine retweeted
Join us on 11/3 for demonstrations, the unveiling of groundbreaking research, and in-depth conversations from the front lines of the cancer community. Register for the #PeopleVCancer summit, underwritten by @FoundationATCG, @PhRMA, & @TakedaPharma, here: on.theatln.tc/z3RBxoK
Foundation Medicine retweeted
At the 5th #PeopleVCancer summit, @TheAtlantic will explore the scientific breakthroughs reshaping patient care and treatment, and how they've renewed community optimism. Register for this event underwritten by @FoundationATCG, @PhRMA, & @TakedaPharma : on.theatln.tc/ttgwI5k
Foundation Medicine retweeted
Just published: Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced #GastroesophagealCancer. Read more in this study by @RyonGraf et al.
https://nitter.gq/t.co/tuoWDYWacZ
@FoundationATCG #openaccess
Foundation Medicine retweeted
#Genomic profiling of 7,494 sarcomas across 44 histologies using #targetedsequencing reveals potential therapeutic targets
#CancerResearch by Gounder et al. @DX_Jin @MSKCancerCenter @FoundationATCG
@NatResCancer
go.nature.com/3Hv45Xr
Foundation Medicine retweeted
Looking forward to hearing from @PritiHegde Chief Scientific Officer of @FoundationATCG #PMWC22 in Silicon Valley on June 29. Her talk is part of the Liquid Biopsy (full-day) track dedicated to the latest technical advancements pmwcintl.com/program/?pmwc-p…

























